Mesenchymal stromal cell quality evaluation method
A single-cell transcriptome analysis and supervised machine learning-based method addresses the lack of standardized quality evaluation for mesenchymal stromal cells, providing a quantitative assessment of cell quality and reducing safety risks through a predictive model.
Patent Information
- Application Number
- JP2024531610
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-14
- Filing Date
- 2022-12-16
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-12-16
AI Technical Summary
Current methods lack standardized and unified norms for evaluating mesenchymal stromal cell quality, leading to heterogeneity issues and safety risks in clinical applications, as they fail to accurately assess the influence of microenvironments on cell quality and quantify cell quality effectively.
A method utilizing single-cell transcriptome analysis and supervised machine learning to determine characteristic genes and weighting coefficients, enabling the construction of a mesenchymal stromal cell quality prediction model that quantitatively evaluates cell quality based on gene expression levels.
The method provides a standardized approach to assess mesenchymal stromal cell quality, accurately predicting cell state and fate, and identifying high-quality cells, thereby reducing safety risks and heterogeneity.
Smart Images

Figure 2024543933000001_ABST
Abstract
Description
[Technical field]
[0001] [CROSS REFERENCE TO RELATED APPLICATIONS] This application claims priority to Chinese Patent Application No. 202210047039.3, filed on January 14, 2022, the entire contents of which are incorporated herein by reference.
[0002] [Technical field] The present invention relates to the technical field of mesenchymal stromal cells, and relates to a method for evaluating the quality of mesenchymal stromal cells, in particular to a method for evaluating the quality of mesenchymal stromal cells based on the expression levels of characteristic genes and the weighting coefficients of the characteristic genes. [Background technology]
[0003] Mesenchymal stromal cell therapy is expected to fundamentally change the clinical dilemmas of intractable diseases faced by conventional medicine by restoring tissue functions and treating the root causes of degenerative diseases, and is the future direction of medical development.
[0004] Obtaining sufficient mesenchymal stromal cells through appropriate expansion culture is a necessary prerequisite for supporting research and applications of mesenchymal stromal cells. Meanwhile, during the proliferation process, different microenvironments can cause changes in gene expression and heterogeneity in mesenchymal stromal cells of the same origin. Such heterogeneity greatly hinders scientific research on mesenchymal stromal cells and poses a fatal risk to the clinical application of mesenchymal stromal cells. Therefore, testing for heterogeneity during the proliferation process of mesenchymal stromal cells is an important prerequisite for the clinical development of mesenchymal stromal cell therapy.
[0005] Although single-cell RNA sequencing (scRNA-seq) offers the possibility of investigating cell-to-cell heterogeneity and can preliminarily analyze the heterogeneity of cell subpopulations based on gene expression profiles, it cannot clarify the relationship between cell heterogeneity and cell quality, nor can it quantitatively determine mesenchymal stromal cell quality.
[0006] CN113061638A provides a mesenchymal stromal cell evaluation system that performs sterility tests, safety tests, cell activity tests, and cell morphology tests on mesenchymal stromal cells.
[0007] However, the prior art lacks sound and unified norms and standards for mesenchymal stromal cell quality evaluation, cannot accurately show the effects of microenvironment on mesenchymal stromal cells, and cannot solve the safety problems in mesenchymal stromal cell therapy. The mesenchymal stromal cell industry still faces major challenges such as incomplete quality control systems, incomplete mechanism research, and non-standard clinical applications. Summary of the Invention
[0008] In view of the shortcomings of the prior art and practical needs, the present invention provides a method for evaluating the quality of mesenchymal stromal cells, which establishes an important classification standard for mesenchymal stromal cell quality at the single-cell level. Based on single-cell transcriptome analysis and a clustering method for functional cell subpopulations, a single-cell gene expression dataset of mesenchymal stromal cells with quality attribute labels is obtained. A mesenchymal stromal cell quality prediction model is constructed by a supervised machine learning method, and the feature genes and the weighting coefficients of the feature genes related to the quality of mesenchymal stromal cells are determined. The quality risk caused by the heterogeneity of mesenchymal stromal cells is quantitatively determined.
[0009] First, in the present invention, Obtaining expression levels of characteristic genes associated with mesenchymal stromal cell quality; Calculating a mesenchymal stromal cell quality score based on the expression levels of the feature genes and the weighting coefficients of the feature genes; To evaluate mesenchymal stromal cell quality based on mesenchymal stromal cell quality score A method for evaluating the quality of mesenchymal stromal cells is provided, comprising:
[0010] Although clinical mesenchymal stromal cells have the same cell biological properties, they will have heterogeneous changes due to the influence of the microenvironment. In order to indicate the heterogeneity of cells, predict the cell state / fate, and further evaluate the quality of mesenchymal stromal cells, the characteristic genes and the weight coefficients of the characteristic genes related to the quality of mesenchymal stromal cells are determined by means of bioinformatics, and the quality of mesenchymal stromal cells is further evaluated based on the expression levels of the characteristic genes and the weight coefficients of the characteristic genes.
[0011] In the present invention, the feature genes and the weighting coefficients of the feature genes related to the mesenchymal stromal cell quality are determined by learning the expression dataset of single-cell genes with quality attribute labels with a supervised machine learning model, and the feature genes related to the mesenchymal stromal cell quality can accurately define the differences between different mesenchymal stromal cells. Based on the expression levels of the feature genes and the weighting coefficients of the feature genes of the tested mesenchymal stromal cell samples, a quality score of the mesenchymal stromal cells can be calculated to quantitatively evaluate the mesenchymal stromal cell quality.
[0012] Preferably, the mesenchymal stromal cell quality-related signature genes are mesenchymal stromal cell quality-related signature genes determined at the single cell level.
[0013] Specifically, the method for determining the feature genes and the weighting coefficients of the feature genes includes the following steps: obtaining single-cell gene expression data and specific quality attributes of mesenchymal stromal cells to form a dataset divided into a training set and a test set; Training a supervised machine learning model using the training set, adjusting parameters of the supervised machine learning model using cross-validation and a test set, and determining a mesenchymal stromal cell quality prediction model; The method includes determining the characteristic genes and the weighting coefficients of the characteristic genes related to the quality of mesenchymal stromal cells using the mesenchymal stromal cell quality prediction model.
[0014] In the present invention, single-cell gene expression data of mesenchymal stromal cells with known quality attribute labels is used as a dataset, which is randomly divided into a training set and a test set at a certain ratio, and a supervised machine learning model is trained (the number of features of the supervised machine learning model is determined by the training set, and the parameters are adjusted by the test set to optimize the supervised machine learning model), and a model with good accuracy, precision, recall and F1 score is obtained as a mesenchymal stromal cell quality prediction model. The feature genes related to the quality of mesenchymal stromal cells and their weights are determined by the final model.
[0015] The method for obtaining single cell gene expression data of mesenchymal stromal cells comprises: This involves obtaining single-cell gene expression data of mesenchymal stromal cells by performing single-cell RNA sequencing on the mesenchymal stromal cells.
[0016] The method for determining the specific quality attributes is as follows: determining specific quality attributes based on the culture microenvironment of mesenchymal stromal cells; Determining specific quality attributes based on apparent genetic data of single-cell genes of mesenchymal stromal cells; or This involves determining certain quality attributes based on single-cell gene expression data of the mesenchymal stromal cells.
[0017] determining certain quality attributes based on single cell gene expression data of the mesenchymal stromal cells, Performing pathway enrichment analysis on single-cell gene expression data of mesenchymal stromal cells and calculating pathway enrichment scores for each mesenchymal stromal cell to obtain a pathway score matrix; This involves performing bioinformatics analysis on the pathway score matrix to obtain clustering results of mesenchymal stromal cells as a specific quality attribute.
[0018] Preferably, performing a bioinformatics analysis on the pathway score matrix comprises: This involves performing dimensionality reduction and clustering procedures on the pathway score matrix.
[0019] In the present invention, a pathway score matrix is constructed by combining traditional cell subpopulation clustering, differential gene analysis and pathway enrichment analysis. In the pathway score matrix, each row represents the expression status of a pathway in different mesenchymal stromal cells, each column represents a cell index, and each grid data represents the expression status of a specific pathway in a specific mesenchymal stromal cell. This pathway-based functional clustering method has achieved the effect of quickly revealing the functional differences of mesenchymal stromal cells.
[0020] Preferably, the method for obtaining the expression level of the characteristic gene includes common gene quantification methods in the art, such as single-cell sequencing, high-throughput sequencing, microarray chip, qPCR, etc. Preferably, the expression level of the characteristic gene is obtained by single-cell sequencing.
[0021] Preferably, the function of the quality score of said mesenchymal stromal cells is as follows:
number
[0022] In the present invention, the expression levels of the characteristic genes in the mesenchymal stromal cell samples are examined, and the weighted sum is calculated and incorporated into the above function to obtain the mesenchymal stromal cell quality score. The higher the score, the higher the quality risk of the mesenchymal stromal cell.
[0023] Preferably, the method for evaluating the quality of mesenchymal stromal cells based on the mesenchymal stromal cell quality score comprises: if the quality score of the mesenchymal stromal cells is equal to or greater than the threshold value of the mesenchymal stromal cell quality risk, the mesenchymal stromal cells are quality risk mesenchymal stromal cells; When the quality score of the mesenchymal stromal cells is < the mesenchymal stromal cell quality risk threshold, it includes that the mesenchymal stromal cells are non-quality risk mesenchymal stromal cells.
[0024] Preferably, the method for determining a threshold value of a mesenchymal stromal cell quality risk comprises: analyzing the data set for a mesenchymal stromal cell quality score according to a receiver operating characteristic curve, the highest value of which is a mesenchymal stromal cell quality risk threshold, and an area under the curve; The dataset comprises single-cell gene expression data of mesenchymal stromal cells with known particular quality attribute labels.
[0025] Preferably, the supervised machine learning model includes any one of a perceptron model, a K nearest neighbors model, a naive Bayes model, a decision tree model, a logistic regression, a support vector machine, a random forest, a boosting model, an EM algorithm, or a conditional random field. good
[0026] Preferably, the mesenchymal stromal cell quality-related characteristic genes include at least three genes selected from the group consisting of TAGLN, EFEMP1, TPM1, CLU, PTX3, IER3, IGFBP7, MFAP5, IL6, LUM, SERPINE2, CRIM1 and RHOB. Most preferably, the mesenchymal stromal cell quality-related characteristic genes include TAGLN, EFEMP1, TPM1, CLU, PTX3, IER3, IGFBP7, MFAP5, IL6, LUM, SERPINE2, CRIM1 and RHOB.
[0027] Preferably, the mesenchymal stromal cells include any one or a combination of at least two of adult mesenchymal stromal cells, embryonic mesenchymal stromal cells, induced pluripotent mesenchymal stromal cells, or mesenchymal stromal cells transformed from mature somatic cells and their derived cells.
[0028] Preferably, the mesenchymal stromal cells include any one or a combination of at least two of mesenchymal stromal cells, mesenchymal stromal cells, multipotent stromal cells, multipotent mesenchymal stromal cells, or medicinal signaling cells.
[0029] Preferably, the mesenchymal stromal cells include any one or a combination of at least two of adipose-derived mesenchymal stromal cells, umbilical cord mesenchymal stromal cells, placenta-derived mesenchymal stromal cells, bone marrow mesenchymal stromal cells, dental marrow mesenchymal stromal cells, menstrual blood-derived mesenchymal stromal cells, amniotic epithelial mesenchymal stromal cells, and bronchial basal cells.
[0030] As a preferred technical solution, the present invention provides a method for evaluating the quality of mesenchymal stromal cells, including:
[0031] 1. Subpopulation Clustering To preprocess single-cell RNA sequencing data of mesenchymal stromal cells and obtain single-cell gene expression data of mesenchymal stromal cells; performing pathway enrichment analysis on the single-cell gene expression data of mesenchymal stromal cells, calculating the classical pathway enrichment score in each mesenchymal stromal cell, and obtaining a pathway score matrix; Normalization, dimensionality reduction, clustering and visualization processes are performed on the pathway score matrix to obtain functional clustering results of single-cell subpopulations of mesenchymal stromal cells as specific quality attributes of mesenchymal stromal cells.
[0032] 2. Identification of Subpopulations forming the obtained single-cell gene expression data of mesenchymal stromal cells labeled with specific quality attributes into a dataset divided into a training set and a test set; A supervised machine learning model is trained by the training set, and parameters of the supervised machine learning model are adjusted by cross-validation and a test set to determine a mesenchymal stromal cell quality prediction model, characteristic genes related to mesenchymal stromal cell quality, and weight coefficients of the characteristic genes.
[0033] 3. Mesenchymal Stromal Cell Quality Scoring Obtaining expression levels of signature genes in a mesenchymal stromal cell sample; Calculating a mesenchymal stromal cell quality score based on the expression levels of the feature genes and the weight coefficients of the feature genes. The function of the quality score of the mesenchymal stromal cells is as follows:
number
[0034] 4. Assessment of Mesenchymal Stromal Cell Quality The quality of the mesenchymal stromal cells is evaluated based on the mesenchymal stromal cell quality score. if the quality score of the mesenchymal stromal cells is equal to or greater than the threshold value of the mesenchymal stromal cell quality risk, the mesenchymal stromal cells are quality risk mesenchymal stromal cells; If the quality score of the mesenchymal stromal cells is < the mesenchymal stromal cell quality risk threshold, the mesenchymal stromal cells are non-quality risk mesenchymal stromal cells. The method for determining a threshold value of a mesenchymal stromal cell quality risk comprises: analyzing the data set for a mesenchymal stromal cell quality score according to a receiver operating characteristic curve, the highest value of which is a mesenchymal stromal cell quality risk threshold, and an area under the curve; The dataset comprises single-cell gene expression data of mesenchymal stromal cells labeled with known specific quality attributes.
[0035] Secondly, in the present invention, obtaining single cell gene expression data and specific quality attributes of mesenchymal stromal cells to form a dataset divided into a training set and a test set; A method for constructing a mesenchymal stromal cell quality prediction model is provided, the method including: training a supervised machine learning model using a training set; adjusting parameters of the supervised machine learning model through cross-validation and testing using a test set; and determining a mesenchymal stromal cell quality prediction model.
[0036] Preferably, the method for obtaining single cell gene expression data and specific quality attributes of said mesenchymal stromal cells comprises: Obtain single-cell gene expression data of mesenchymal stromal cells by performing single-cell RNA sequencing on mesenchymal stromal cells. Performing pathway enrichment analysis on the single-cell gene expression data of mesenchymal stromal cells and calculating the pathway enrichment score for each mesenchymal stromal cell to obtain a pathway score matrix; and This includes performing bioinformatics analysis on the pathway score matrix to obtain clustering results of mesenchymal stromal cells as specific quality attributes of mesenchymal stromal cells.
[0037] Preferably, the bioinformatics analysis of the pathway score matrix of the mesenchymal stromal cell comprises: This involves performing dimensionality reduction and clustering procedures on the pathway score matrix. Preferably, the method further comprises: The method includes determining the characteristic genes and the weighting coefficients of the characteristic genes related to the quality of mesenchymal stromal cells using the mesenchymal stromal cell quality prediction model.
[0038] Thirdly, in the present invention, performing pathway enrichment analysis on single-cell gene expression data of mesenchymal stromal cells, calculating pathway enrichment scores in each mesenchymal stromal cell, and obtaining a pathway score matrix; A method for single-cell functional clustering of mesenchymal stromal cells is provided, comprising: performing bioinformatics analysis on the pathway score matrix to obtain single-cell subpopulations of mesenchymal stromal cells.
[0039] Preferably, performing a bioinformatics analysis on the pathway score matrix comprises: This involves performing dimensionality reduction and clustering procedures on the pathway score matrix.
[0040] Preferably, the method further comprises: The method includes analyzing differentially expressed genes of single-cell subpopulations of mesenchymal stromal cells, selecting a single-cell subpopulation in which one or more differentially expressed genes associated with a pathway are present, and performing dimensionality reduction and clustering processing using the differentially expressed genes to obtain single-cell functional clustering results of mesenchymal stromal cells.
[0041] Preferably, the functional pathway may be a pro-embolism related pathway including an intrinsic pathway formed in a fibrin clot, an extrinsic pathway formed in a fibrin clot, and a common pathway formed in a fibrin clot.
[0042] Fourth, the present invention provides a combination of characteristic genes that includes at least three genes selected from the group of genes consisting of TAGLN, EFEMP1, TPM1, CLU, PTX3, IER3, IGFBP7, MFAP5, IL6, LUM, SERPINE2, CRIM1 and RHOB, or that consists of at least three genes selected from the group of genes.
[0043] Fifth, the present invention provides an application for evaluating the quality of mesenchymal stromal cells using genes including at least three genes selected from the group consisting of TAGLN, EFEMP1, TPM1, CLU, PTX3, IER3, IGFBP7, MFAP5, IL6, LUM, SERPINE2, CRIM1 and RHOB.
[0044] Sixth, the present invention provides a server including a processor and a memory storing instructions executable by the processor, the server being configured so that the processor executes the method for evaluating mesenchymal stromal cell quality described in the first aspect of the present invention, the method for constructing a mesenchymal stromal cell quality prediction model described in the second aspect of the present invention, or the method for single-cell functional clustering of mesenchymal stromal cells described in the third aspect of the present invention.
[0045] Seventh, the present invention provides a computer readable medium storing a computer program for executing the method for evaluating mesenchymal stromal cell quality described in claim 1 of the present invention, the method for constructing a mesenchymal stromal cell quality prediction model described in claim 2 of the present invention, or the single-cell functional clustering method for mesenchymal stromal cells described in claim 3 of the present invention.
[0046] Compared with the prior art, the present invention has the following beneficial effects: (1) The method for evaluating the quality of mesenchymal stromal cells of the present invention is based on single-cell RNA sequencing technology and a functional cell subpopulation clustering method, in which a standard profile of mesenchymal stromal cell quality is constructed at the single-cell level, and a mesenchymal stromal cell quality prediction model is constructed by a supervised machine learning model using this standard profile of mesenchymal stromal cell quality as a dataset. (2) The present invention uses a mesenchymal stromal cell quality prediction model to determine the characteristic genes and weight coefficients of the characteristic genes related to the quality of mesenchymal stromal cells. Based on the weighted sum of the characteristic genes related to the quality of mesenchymal stromal cells, the quality of mesenchymal stromal cells can be accurately and quantitatively evaluated, which is a regular, complete and unified method for evaluating the quality of mesenchymal stromal cells; (3) The method for evaluating the quality of mesenchymal stromal cells of the present invention has the effect of accurately and quantitatively indicating cellular heterogeneity, predicting cell state / fate, and further evaluating the mass of mesenchymal stromal cells under the influence of the microenvironment. (4) The method for evaluating the quality of mesenchymal stromal cells of the present invention can be used to screen for high-quality mesenchymal stromal cells. [Brief description of the drawings]
[0047] [Figure 1A] FIG. 1A is a growth curve of D1M1-P5. [Figure 1B] FIG. 1B is a growth curve of D1M2-P5. [Figure 1C] FIG. 1C is a cell cycle analysis of D1M1-P5. [Figure 1D] FIG. 1D is a cell cycle analysis of D1M2-P5. [Figure 1E] FIG. 1E shows the apoptotic group of D1M1-P5. [Figure 1F] FIG. 1F shows the apoptotic group of D1M2-P5. [Figure 1G] FIG. 1G shows adipogenic, osteogenic and chondrogenic differentiation of D1M1-P5. [Figure 1H] FIG. 1H shows adipogenic, osteogenic and chondrogenic differentiation of D1M2-P5. [Figure 2A] FIG. 2A shows lung tissue and HE staining results when D1M1-P5, D1M2-P5, or saline was injected into mice (black arrows indicate venous thrombus formation). [Figure 2B] FIG. 2B shows the density of emboli expressed in each 10× field (*p<0.05). [Figure 2C] FIG. 2C shows the results of lung fluorescence in mice injected with D1M1-P5, D1M2-P5, or saline. [Figure 2D] FIG. 2D shows the number of PKH26+ expressed cells in each 10× field. [Figure 3A] FIG. 3A shows the clustering results of D1M1-P5 and D1M2-P5 cell subpopulations (0, 1, 2, 3, 4, and 5 represent different mesenchymal stromal cell subpopulations (clusters), respectively). [Figure 3B] FIG. 3B shows the expression of different mesenchymal stromal cell subpopulations for risk genes based on the GO-BP database (C0, C1, C2, C3, C4, and C5 (corresponding to mesenchymal stromal cell subpopulations 0, 1, 2, 3, 4, and 5 in FIG. 3A) represent different mesenchymal stromal cell subpopulations, respectively). [Figure 3C]FIG. 3C shows the expression of different mesenchymal stromal cell subpopulations for risk genes based on the KEGG database (C0, C1, C2, C3, C4, and C5 (corresponding to mesenchymal stromal cell subpopulations 0, 1, 2, 3, 4, and 5 in FIG. 3A ) represent different mesenchymal stromal cell subpopulations, respectively). [Figure 4] FIG. 1 is a schematic diagram of the mechanism of the functional clustering method. [Figure 5A] FIG. 5A shows the functional cell subpopulation clustering results obtained by the ssGSEA scoring function (A2105C2P5 (i.e., D1M1-P5) were all quality risk mesenchymal stromal cells, and A2105C3P5 (i.e., D1M2-P5) were all non-quality risk mesenchymal stromal cells). [Figure 5B] FIG. 5B shows the functional cell subpopulation clustering results obtained by the AUCell scoring function (A2105C2P5 (i.e., D1M1-P5) were all quality risk mesenchymal stromal cells, and A2105C3P5 (i.e., D1M2-P5) were all non-quality risk mesenchymal stromal cells). [Figure 5C] FIG. 5C shows the functional cell subpopulation clustering results obtained by the Seurat scoring function (A2105C2P5 (i.e., D1M1-P5) were all quality risk mesenchymal stromal cells, and A2105C3P5 (i.e., D1M2-P5) were all non-quality risk mesenchymal stromal cells). [Figure 6] FIG. 1 is a schematic diagram of cross-culture of mesenchymal stromal cells. [Figure 7A] Figure 7A shows the functional cell subpopulation clustering results obtained by the ssGSEA scoring function (D1M1-P3, D1M1-P5, and D1M2 / M1-P5 were all quality risk mesenchymal stromal cells, and D1M2-P3, D1M2-P5, and D1M1 / M2-P5 were all non-quality risk mesenchymal stromal cells). [Figure 7B]Figure 7B shows the functional cell subpopulation clustering results obtained by the AUCell scoring function (D1M1-P3, D1M1-P5, and D1M2 / M1-P5 were all quality risk mesenchymal stromal cells, and D1M2-P3, D1M2-P5, and D1M1 / M2-P5 were all non-quality risk mesenchymal stromal cells). [Figure 7C] Figure 7C shows the functional cell subpopulation clustering results obtained by the Seurat scoring function (D1M1-P3, D1M1-P5, and D1M2 / M1-P5 were all quality risk mesenchymal stromal cells, and D1M2-P3, D1M2-P5, and D1M1 / M2-P5 were all non-quality risk mesenchymal stromal cells). [Figure 8A] FIG. 8A shows lung tissue and HE staining results when D1M1-P3, D1M2-P3, D1M2 / M1-P5, D1M2 / M1-P5, or saline was injected into mice (black arrows indicate venous thrombus formation). [Figure 8B] FIG. 8B shows the density of emboli expressed in each 10× field (*p<0.05). [Figure 9A] FIG. 9A is a heat map of the most differentially expressed genes of functional subpopulations of mesenchymal stromal cells cultured in M1 medium. [Figure 9B] FIG. 9B is a heat map of differentially expressed genes atop functional subpopulations of mesenchymal stromal cells cultured in M2 medium. [Figure 9C] FIG. 9C shows the functional clustering results of mesenchymal stromal cells cultured in M1 medium (0 indicates quality risk mesenchymal stromal cells, and 1 indicates non-quality risk mesenchymal stromal cells). [Figure 9D] FIG. 9D shows the functional clustering results of mesenchymal stromal cells cultured in M2 medium (0 indicates non-quality risk mesenchymal stromal cells, and 1 indicates quality risk mesenchymal stromal cells). [Figure 10] FIG. 1 is a schematic diagram of the construction mechanism of the mesenchymal stromal cell quality prediction model. [Figure 11]This shows the change curves of cross-validation accuracy rate with increasing gene quantity in the recursive feature reduction (RFE) process, and the inflection points of eight expanded different RFE change curves (M1, M2, M3, M4, M5, M6, M7, and M8). [Figure 12] This is the quality score threshold with the highest sensitivity and specificity for classifying mesenchymal stromal cells into mesenchymal stromal cells with or without quality risk in the four measurement datasets. [Figure 13A] FIG. 13A is a density distribution of mesenchymal stromal cell quality scores for test set 1. [Figure 13B] FIG. 13B is a density distribution of mesenchymal stromal cell quality scores for test set 2. [Figure 13C] FIG. 13C is a density distribution of mesenchymal stromal cell quality scores for test set 3. [Figure 13D] FIG. 13D is the density distribution of mesenchymal stromal cell quality scores for test set 4. [Figure 14] The quality of D1M1 / M2-P5 and D1M2 / M1-P5 is predicted based on the characteristic genes and the weighting coefficients of the characteristic genes determined by the mesenchymal stromal cell quality prediction model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0048] In order to further explain the technical means and effects of the present invention, the present invention will be further described below in combination with the embodiments and drawings. It is understood that the specific embodiments described herein do not limit the present invention, but merely serve to interpret the present invention. Various modifications and variations to the method and system of the present invention are obvious to those skilled in the art and do not depart from the scope and substantial content of the present invention. Although the present invention has been described in combination with specific preferred embodiments, it should be understood that the present invention should not be unduly limited to these specific embodiments, as per the claims, and various modifications and additions can be made to the embodiments within the scope of the present invention. Of course, various modifications to the embodiments made by those skilled in molecular biology and related fields to carry out the present invention are all within the scope of the claims.
[0049] For embodiments in which specific techniques or conditions are not specified, the techniques and conditions described in the literature in the field or the product specifications are followed. Reagents or equipment without a manufacturer name are all genuine products that can be purchased through official channels.
[0050] definition As used above and below, "mesenchymal stromal cells" refers to a type of cell that is relatively undifferentiated, capable of differentiation, capable of actively dividing and cycling, and capable of providing the appropriate stimuli for mature differentiated and functional cell lines. The properties defined for said mesenchymal stromal cells include (a) not being terminally differentiated themselves, (b) being capable of dividing indefinitely throughout the life of an animal, (c) being a type of mesenchymal stromal cell, rather than a mixture of multiple types of mesenchymal stromal cells and / or somatic cells, with outcomes characterized by consistent cell markers, and (d) when mesenchymal stromal cells divide, each daughter cell can either remain as a mesenchymal stromal cell or undergo a process that irreversibly induces terminal differentiation.
[0051] As described above and below, "multipotent mesenchymal stromal cells" or "mesenchymal stromal cells" are multipotent mesenchymal stromal cells that can differentiate into multiple cell types. Multipotent mesenchymal stromal cells have been shown to differentiate in vitro or in vivo into cell types including osteoblasts, chondrocytes, muscle cells, and adipocytes. Mesenchyme is an embryonic connective tissue derived from the mesoderm that differentiates into hematopoietic and connective tissues, although multipotent mesenchymal stromal cells do not differentiate into hematopoietic cells.
[0052] As mentioned above or below, "mesenchymal stromal cell quality" refers to any one of the above-mentioned relevant factors of mesenchymal stromal cell safety, in which mesenchymal stromal cells are heterogeneous due to the influence of the microenvironment, and such heterogeneity may lead to quality risks. Clinical grade mesenchymal stromal cells are not a mixture of multiple types of mesenchymal stromal cells and / or mesenchymal stromal cells and somatic cells, but contain one type of mesenchymal stromal cells, and require rigorous third-party quality testing and laboratory testing closely related to the safety, efficacy and consistency of mesenchymal stromal cells, including cell viability, biological function, tumorigenicity, embolicity, immunogenicity, microbial, mycoplasma, endotoxin testing, etc. In order to avoid acute or subacute severe adverse reactions such as fever, allergy, bacteremia, etc. during or after transplantation, qualified mesenchymal stromal cells should further undergo release testing before their transplantation, and further undergo compatibility testing against microbial, mycoplasma and endotoxin.
[0053] As described above or below, "characteristic genes related to mesenchymal stromal cell quality" refers to genes that define mesenchymal stromal cell quality categories. High expression of these genes increases or decreases the quality risk of mesenchymal stromal cells.
[0054] As stated above and below, "expression level" refers to the expression level of a gene.
[0055] As described above or below, the "mesenchymal stromal cell quality score" refers to a score calculated by the following calculation function based on the expression levels of the characteristic genes and the weighting coefficients of each characteristic gene determined by the mesenchymal stromal cell quality prediction model.
[0056]
number
[0057] As described above or below, the "gene expression level" refers to the expression level of a specific gene in a cell measured by a general method in the field of molecular biology. For example, it includes the value of the hybridization level measured as the fluorescence intensity between the probe nucleic acid immobilized on the surface of a DNA chip plate (measurement data) and the estimated value of the gene expression level obtained based on the value.
[0058] As described above or below, a "specific quality attribute" refers to the clustering result of a subpopulation of a single mesenchymal stromal cell determined by a subpopulation clustering method, i.e., "quality risk mesenchymal stromal cells" or "non-quality risk mesenchymal stromal cells."
[0059] As described above or below, a "pathway score matrix" is a matrix of pathway identities in columns and cell indices in rows, with data in each grid representing the expression status of a particular pathway in a particular mesenchymal stromal cell. Data analysis methods (including supervised and unsupervised data analysis, as well as bioinformatics methods) are presented in Brazma and ViIo J, 2000, FEBS Lett 480(1):17-24.
[0060] As described above or below, a "pathway" is any pathway related to the function of mesenchymal stromal cells, such as developmental signaling pathways such as Notch, WNT, Hedgehog, Hippo, and NANOG, and oncogenic pathways such as NF-κB, MAPK, PI3K, and EGFR. Those skilled in the art are aware of the design of cellular pathways related to the function of mesenchymal stromal cells. In the present invention, it may be any pathway related to mesenchymal stromal cell oncogenicity, immunogenicity, etc. Preferred pathways include the intrinsic pathway formed in a fibrin clot, the extrinsic pathway formed in a fibrin clot, and the common pathway formed in a fibrin clot.
[0061] In the following examples, an example of the risk of mesenchymal stromal cell-induced embolism associated with mesenchymal stromal cell quality and closeness is described, but those skilled in the art can understand that the tumorigenicity and immunogenicity of mesenchymal stromal cells can be identified by substantially the same method and means according to the disclosure of the present invention. For example, the characteristic gene associated with tumorigenicity may be c-myc, and the characteristic gene associated with immunogenicity may be dnam-1, mcp-1.
[0062] The risk of mesenchymal stromal cell-induced embolism is the most typical risk of mesenchymal stromal cell application and is one of the most important factors affecting mesenchymal stromal cell quality. In the last 20 years, many clinical cases have been reported in which embolic complications occurred after mesenchymal stromal cell therapy (Woodard, JP et al. Pulmonary cytolytic thrombi: a newly recognized complication of stem cell transplantation. Bone Marrow Transpl 25, 293-300 (2000).; Tatsumi, K. et al. Tissue factor triggers procoagulation in transplanted multipotent mesenchymal stem cells leading to thromboembolism. Biochem Biophys Res Commun 431, 203-209 (2013).). From this, it can be understood that a person skilled in the art can use the evaluation of the risk to evaluate the quality of mesenchymal stromal cells. EXAMPLES
[0063] Example 1: Obtaining and culturing multipotent mesenchymal stromal cells 1. Obtaining Multipotent Mesenchymal Stromal Cells (1) Collection of adipose tissue Adipose tissue was collected from donors (negative for AIDS virus, hepatitis B virus, hepatitis C virus, human T-cell virus, EB virus, cytomegalovirus, and Treponema pallidum) in a sterile environment. Adipose tissue (50-150 mL) was placed in a sealed container to which 100 mL of tissue preservation solution (purchased from TIAN JIN HAO YANG BIOLOGICAL MANUFACTURE Co., Ltd.) had been added beforehand, and was prepared by storing at 2-8°C. 30 mL of tissue preservation fluid was pipetted and tested for bacterial, endotoxin and mycoplasma contamination, and the tissue was then used for isolation of pluripotent mesenchymal stromal cells.
[0064] (2) Isolation of multipotent mesenchymal stromal cells The same volume of Dulbecco's phosphate buffered saline (dPBS) was added to the adipose tissue, the container containing the tissue was sealed, vigorously shaken for 20 seconds, and left to stand for 5 minutes. After the adipose tissue and dPBS were completely separated, the liquid underneath the tissue was discarded, and the adipose tissue was repeatedly washed with dPBS until the liquid underneath was no longer red. A 20 mL aliquot of the washed adipose tissue was placed in a 50 mL centrifuge tube, and the same volume of dPBS was added and centrifuged at 400 g for 5 minutes. The solution was separated into an upper oily layer, a middle adipose tissue layer, and a lower layer of dPBS and blood cell precipitate. The upper oily layer, lower dPBS and blood cell precipitate were removed. Two volumes of 1 mg / mL type I collagenase (purchased from Gibco, catalog number: 17100-017) were added to the adipose tissue. The container with the tissue was sealed and transferred to a thermostatic air shaker preheated to 37° C. The tissue was digested with collagenase at 120 rpm / min for 1 hour.
[0065] (3) Collection of multipotent mesenchymal stromal cells The digested tissue was centrifuged at 500g for 8 minutes at room temperature. After centrifugation, the tissue was separated into an upper oily layer, a middle adipose tissue layer, a lower digestion solution, and a bottom cell precipitate. The upper oily layer, the middle adipose tissue layer, and the bottom digestion solution were discarded. The bottom cell precipitate was resuspended in dPBS, filtered through a 100 μm filter, and centrifuged at 500g for 5 minutes in a 50 mL centrifuge tube. The supernatant was removed to obtain a cell precipitate containing primary human adipose-derived stromal cells (hADSCs). The complete medium was added to the centrifuge tube in the same volume as the adipose tissue, and mixed evenly to thoroughly release the digested cells, obtaining a cell suspension containing primary human adipose-derived stromal cells.
[0066] 2. Culturing Multipotent Mesenchymal Stromal Cells Primary human adipose-derived stromal cells were cultured in different media M1 (αMEM + 10% FBS, αMEM purchased from Thermo Fisher, FBS purchased from ExCell Bio) or M2 (DMEM / F-12 + 5% Helios UltraGRO-Advanced, DMEM / F-12 purchased from Thermo Fisher, Helios UltraGRO-Advanced purchased from Helios BioScience), and the specific steps were as follows:
[0067] (1) Primary culture The cell pellet was resuspended in M1 medium / M2 medium, and 1.5 mL of the cell suspension was inoculated into a T75 cell culture flask to which 8.5 mL of M1 medium / M2 medium had previously been added. After labeling the T75 cell culture flask, it was transferred to a cell culture incubator and cultured at 37°C and 5% CO2. After 24 hours, most of the primary human adipose-derived stromal cells had attached to the wall. The supernatant was removed and 10 mL of M1 medium / M2 medium was added. The medium was then changed every 3 days. Microscopic observation revealed that in addition to primary human adipose-derived stromal cells, the resulting primary cells contained numerous heterocytic cells and matrix components, and had the typical long spindle shape of human adipose-derived stromal cells.
[0068] (2) Subculture When the primary human adipose-derived stromal cells were 50%-70% confluent, the medium was removed and the cells were washed once with 10 mL of dPBS. TM 1.5 mL of -Express (1x) (purchased from Gibco, catalog number: 12604-021) was added and digested for 1-2 minutes. After some cells became round and fell off, the culture flask was gently tapped and 4.5 mL of dPBS was added to terminate the digestion. The liquid was collected in a 50 mL centrifuge tube. After washing once with 10 mL of dPBS, it was centrifuged at 400 g for 5 min. The upper layer was a mixture of the digestion solution and dPBS, and the lower layer was a white precipitate, i.e., a precipitate containing primary human adipose-derived stromal cells. The supernatant was removed, and the white precipitates in the multiple centrifuge tubes were collected in one centrifuge tube and resuspended in M1 medium / M2 medium until the volume reached 30 mL. The cell suspension was then mixed uniformly and used for cell counting. The counted cells were resuspended in M1 medium / M2 medium and counted at 5000-6000 cells / cm. 2 The cells were passaged at a density of 100 x 100 μg / ml. The cell culture flask was labeled with information such as cell batch, passage number, and culture time, and placed in a cell culture incubator. When the cells reached approximately 90% confluence, they were passaged again. The 3rd and 5th passage pluripotent mesenchymal stromal cells were collected and stored under refrigeration, and were named D1M1-P3 (representing pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells derived from donor 1 in M1 medium up to the 3rd passage), D1M2-P3 (representing pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells derived from donor 1 in M2 medium up to the 3rd passage), D1M1-P5 (representing pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells of donor 1 in M1 medium up to the 5th passage), and D1M2-P5 (representing pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells of donor 1 in M2 medium up to the 5th passage).
[0069] Example 2 Quality control of multipotent mesenchymal stromal cells In this example, the refrigerated samples were thawed quickly in a 37°C water bath with continuous stirring, and the multipotent mesenchymal stromal cells were resuspended in pre-warmed dPBS, centrifuged at 400g for 5 min, and washed twice with dPBS. Finally, the multipotent mesenchymal stromal cells (D1M1-P3, D1M2-P3, D1M1-P5, D1M2-P5) were counted and used for quality control.
[0070] 1.Microbiological safety testing (1) Sterility test According to the Chinese Pharmacopoeia 2020 Edition (Part 4) General Provision 1101 Sterility Test Method, the steps are briefly described as follows: After wetting the filter membrane of a disposable triple bacterial collector (purchased from Zhejiang Tailin Bioengineering Co., Ltd.) with 100 mL of 0.9% saline (purchased from SJZ No.4 Pharmaceutical), each hADSC sample was introduced into the bacterial collector for filtration. After filtration, the filter membrane was washed twice with 300 mL of 0.9% saline. Two different media were used: thioglycollate broth for anaerobic and aerobic bacteria testing, and trypticase soy broth (TSB), a soybean-casein-digest medium, for anaerobic and aerobic bacteria testing. Two of the triple bacterial collectors containing samples were each filled with 100 mL of thioglycollate broth and the other with 100 mL of TSB. One mL of 0.9% saline in place of the sample served as a negative control, and Staphylococcus aureus (bacterial loading less than 100 CFU) served as a positive control. After inoculation, the media were gently shaken and incubated under the conditions recommended by the sterility test as follows: the liquid thioglycollate medium was placed at 30-35°C, and the remaining media were placed at 20-25°C and incubated for 14 days. After a total of 14 days of incubation, bacterial growth was observed and recorded on each working day during the incubation period.
[0071] (2) Mycoplasma test According to the Chinese Pharmacopoeia 2020 Edition (Part 4) General Provision 3301 Mycoplasma Testing Method, the steps are briefly described as follows: Mycoplasma broth medium, arginine-containing mycoplasma broth medium, mycoplasma semi-solid medium, and arginine-containing mycoplasma semi-solid medium were prepared according to conventional recipes and sterilized. Next, 800,000 units of sodium penicillin for injection (purchased from Jiangxi Dongfeng Pharmaceutical Co., Ltd.) was redissolved in 1 mL of 0.9% saline to prepare the medium. For every 800 mL of sterilized medium, 200 mL of fetal bovine serum and 800,000 units of sodium penicillin for injection were added, mixed uniformly, and stored at 2-8°C. Four Mycoplasma broth media (10 mL / bottle), four Arginine-containing Mycoplasma broth media (10 mL / bottle), two Mycoplasma semi-liquid media (10 mL / bottle), and two Arginine-containing Mycoplasma semi-liquid media (10 mL / bottle) were inoculated with 1.0 mL of cell sample and cultured at 36 ± 1°C for 21 days, with observations made once every 3 days. On the 7th day after inoculation, two bottles of mycoplasma broth medium inoculated with the cell sample and two bottles of arginine-containing mycoplasma broth medium inoculated with the cell sample were taken and subcultured. With an inoculation volume of 1 mL, each bottle of mycoplasma broth medium was subcultured into two bottles of arginine-containing mycoplasma semi-solid medium and two bottles of mycoplasma broth medium, respectively, and each bottle of arginine-containing mycoplasma broth medium was subcultured into two bottles of arginine-containing mycoplasma semi-solid medium and two bottles of arginine-containing mycoplasma broth medium, respectively, and cultured at 36°C ± 1°C for 21 days, and observed once every 3 to 5 days.
[0072] (3) Endotoxin test According to the Chinese Pharmacopoeia 2020 Edition (Part 4) General Provision 1143 Bacterial Endotoxin Testing Method, the steps are briefly described as follows: The secondary standard (purchased from Zhanjiang A&C Biological Ltd.) was reconstituted with 1 mL of endotoxin test water (purchased from Zhanjiang A&C Biological Ltd.), mixed uniformly on a vortex shaker for 15 minutes, and then gradient dilutions were performed. For each dilution, the solution was mixed on a vortex shaker for 30 seconds, and finally diluted to 4λ and 2λ endotoxin standard solutions. The cell suspension was diluted with endotoxin test water, and each dilution was mixed for 30 seconds on a vortex shaker. The diluted solution was used as the test sample. The dilution rate was less than or equal to the maximum valid dilution factor (MVD), which was calculated by the formula MVD = C × L / λ, where L is the limit value of endotoxin in the sample, C is the concentration of the test sample, and λ is the sensitivity of the Limulus reagent. One test sample was added to the 4λ endotoxin standard solution at a 1:1 volume ratio to serve as an endotoxin positive control. Eight Limulus reagents (purchased from Zhanjiang A&C Biological Ltd.) were reconstituted with 0.1 mL of endotoxin test water. Two Limulus reagents were added with 0.1 mL of endotoxin positive control solution to serve as parallel cell positive control (PPC). Two Limulus reagents were added with 0.1 mL of 2λ endotoxin standard solution to serve as parallel positive control (PC). Two Limulus reagents were added with 0.1 mL of endotoxin test water to serve as parallel negative control (NC). Two Limulus reagents were added with 0.1 mL of cell solution with a dilution rate below MVD to serve as parallel cell test. The reaction tube was placed in a pre-heated endotoxin gel tester and a 60 minute countdown was started. One minute before the 60 minute countdown ended, the reaction tube was removed and the results were observed and recorded. As shown in Table 1, after 14 days, there was no bacterial growth in the collectors containing the mesenchymal stromal cell samples, and the sterility test results of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 were passed. The mycoplasma test results of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 were negative, and the test results were passed. The endotoxin test results of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 were negative, and the test results were passed.
[0073] [Table 1]
[0074] 2. Phenotype analysis The expression of multipotent mesenchymal stromal cell-specific surface markers CD73, CD90, CD105, CD11b, CD19, CD34, CD45 and HLA-DR in hADSC samples was analyzed by flow cytometry (Reference: M. Dominici et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) Vol. 8, No. 4, 315-317). The steps were as follows:
[0075] hADSC samples at passage 3 or 5 were TM Tryptophan-Express (1x) was used to digest the cells at 37°C for 2-3 minutes. When the cells became round and fell off, TM The digestion was terminated by adding PBS (1x) in a volume three times larger than that of -Express (1x). The cell suspension was transferred to a 50 mL centrifuge tube with a pipette and centrifuged at 300 g for 5 min. The cells were washed twice with PBS (1x) to obtain a viable cell density of (0.5–1) x 10 7 The cells were resuspended to a concentration of 10 cells / mL.
[0076] 100 μL of cell suspension was pipetted into the flow tube and incubated with 5 μL of pre-labeled antibodies (FITC-labeled anti-human CD34, FITC-labeled anti-human CD45, FITC-labeled anti-human CD11b, FITC-labeled anti-human HLA-DR, FITC-labeled anti-human CD73, FITC-labeled anti-human CD90, APC-labeled anti-human CD19, and PE-labeled anti-CD105) at room temperature in the dark for 15 min. As controls, FITC-labeled mouse IgG1, APC-labeled mouse IgG1, and PE-labeled mouse IgG1 were added. The antibodies used were purchased from Biolegend.
[0077] Two milliliters of sheath fluid was added to each flow tube, vortexed, and centrifuged at 300 g for 5 minutes, and the supernatant was removed. The cells were resuspended in 300 μL of 1% paraformaldehyde in PBS (1×) and analyzed by flow cytometry.
[0078] As a result, as shown in Table 2, the expression rates of the positive markers CD73, CD90, and CD105 on the surface of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 were more than 95%, and the expression rates of the negative markers CD11b, CD19, CD34, CD45, and HLA-DR on the surface of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 were less than 2%.
[0079] [Table 2]
[0080] 3. Cellular activity test (1) Cell viability analysis The cell suspension was diluted with 0.9% saline and thoroughly mixed with 0.4% trypan blue staining solution at a volume ratio of 9:1. 10 μL of the mixture was pipetted into the counting chamber of the counting plate and observed under a 10x objective lens. The total number of live cells and the total number of dead cells in the four grids were recorded, and the cell viability was calculated according to the following formula: Cell viability (%) = total number of live cells / (total number of live cells + total number of dead cells) x 100% The cell viability of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 was all above 80%.
[0081] (2) Cell proliferation kinetics When the hADSC samples at passage 5 were 80%–90% confluent, TM The cells were digested with -Express (1x). The cell density was adjusted to 3.2x10 5 pieces / mL, 1.6×10 5 pieces / mL, 0.8×10 5 pieces / mL, 0.4×10 5 pieces / mL, 0.2×10 5 pieces / mL, 0.1×10 5 The cells were adjusted to cells / mL and inoculated into a 96-well microplate at 100 μL / well. 100 μL of complete medium was added to the control wells, and six duplicate wells were set up for each group. After culturing for 4 hours at 37°C and 5% CO2, the medium in each well was discarded, and 110 μL / well of CCK8 solution (DMEM / F12 medium (without phenol red):CCK8 (v / v) = 100:10) was added to each well, followed by incubation for 2 hours at 37°C and 5% CO2. The optical density (OD450) at a wavelength of 450 nm was measured using a multi-function microplate reader. The average OD450 of the control wells was normalized to obtain ΔOD450 values for wells with different cell densities. Curve fitting was performed by linear regression using ΔOD450 as the horizontal axis and cell number as the vertical axis. In a parallel experiment, hADSC samples at passage 5 were cultured at 1 × 10 4Cells were plated at a density of 100 cells / well into 96-well microplates. 100 μL of complete medium was added to control wells. Eight plates were prepared with six replicate wells for each group. The cells were counted every day until day 8. The medium in each well was discarded, and 110 μL / well of CCK8 solution (DMEM / F12 medium (without phenol red):CCK8 (v / v)=100:10) was added, followed by incubation at 37°C and 5% CO2 for 2 hours. OD450 was measured using a multi-function microplate reader. The average OD450 of the control wells was normalized to obtain the delta OD450 value of the well. The cell number of each well was calculated based on the curve by linear regression. A growth curve was constructed from the average values, and the population doubling time was calculated from the growth curve. Figures 1A and 1B show the proliferation curves of D1M1-P5 and D1M2-P5, respectively, in which hADSCs entered the logarithmic proliferation phase after 3 days of culture, entered the stationary phase after 6 days, and began to decline in proliferation ability after 7 days. The population doubling time of D1M1-P5 was 37.5 h, and that of D1M2-P5 was 21.9 h.
[0082] (3) Cell cycle analysis hADSC samples at passage 3 or 5 were TM The cells were digested with 1×-Express (1×) at 37°C for 2–3 min, centrifuged at 1000 rpm for 3–5 min, and the supernatant was carefully discarded. The cell mass was washed twice with 1 mL of pre-chilled PBS (1×) to obtain a cell mass with a density of 1×10 6 The mixture was resuspended to cells / mL. 1 mL of the cell suspension was added drop by drop to 4 mL of pre-chilled 95% ethanol solution while vortexing at low speed (operated on ice). After the cells were mixed uniformly, they were fixed at 4°C for more than 2 hours. Next, the cells were precipitated by centrifugation at 1000 rpm for 3 to 5 minutes. The cells were washed twice with 5 mL of pre-chilled PBS (1x), and the bottom of the centrifuge tube was gently tapped to disperse the cells appropriately and avoid cell aggregation. According to Table 3, a cell cycle and apoptosis detection kit (purchased from Beijing 4A Biotech Co., Ltd.) was used to prepare propidium iodide solution according to the number of samples to be tested. Then, 0.4 mL of propidium iodide solution was added to the cell sample, the cell pellet was slowly resuspended, and incubated at 37°C in the dark for 30 minutes. After washing twice with PBS (1x), the cells were resuspended in PBS (1x) and the cell cycle measurement using flow cytometry was completed within 24 hours.
[0083] [Table 3]
[0084] As shown in the cell cycle analysis results in Figures 1C and 1D, the percentages of D1M1-P5 in the G1, S and G2 phases were 85.69%, 12.56% and 1.75%, respectively, and the percentages of D1M2-P5 in the G1, S and G2 phases were 89.07%, 6.42% and 4.51%, respectively.
[0085] (4) Apoptosis test Tryple 5th passage hADSC samples TM The cells were digested with 1x Binding Buffer (purchased from Beijing 4A Biotech Co., Ltd.) for 2-3 minutes at 37°C and centrifuged at 1000 rpm for 3-5 minutes. The supernatant was carefully discarded. The cell pellets were resuspended in 0.8 mL of 1x Binding Buffer (purchased from Beijing 4A Biotech Co., Ltd.). Density is (2~5)×10 5 200 μL of hADSC samples at 100 μg / mL were added to each flow tube and incubated with 5 μL of Annexin-V-FITC for 10 min in the dark. After centrifugation, cells were resuspended in 200 μL of binding buffer and then incubated with 5 μL of propidium iodide before flow cytometry analysis. As a result, as shown in Figures 1E and 1F, in D1M1-P5, the cell viability was 92.0% and the apoptosis rate was 5.75%, and in D1M2-P5, the cell viability was 91.4% and the apoptosis rate was 0.52%.
[0086] 4. Biological activity analysis (1) Adipogenic differentiation Before the experiment, solutions A and B were prepared according to the instructions for the OriCell kit (purchased from Cyagen Biosciences Inc., catalog number: HUXMD-90031) used for adipogenic differentiation of human adipose-derived mesenchymal stromal cells, and then the following steps were performed. 2 x 10 cells 4 cell / cm 2 The cells were seeded at a density of 100×1000×1000 in a 6-well plate, 2 mL of complete medium was added to each well, and the cells were cultured at 37° C. and 5% CO until cell confluence reached 100%. The culture supernatant was discarded. The cells were incubated in 2 mL of solution A for 3 days, then replaced with 2 mL of solution B and incubated for 24 hours. After repeating this three times, the cells were subsequently cultured in solution B for 4 to 7 days until the lipid droplets became sufficiently large and round. The cells were washed, fixed with 4% paraformaldehyde solution, and stained with 0.5% Oil Red O for 20 min at room temperature. After washing three times with PBS (1×), images were taken with an inverted phase contrast microscope.
[0087] (2) Osteogenic differentiation Before the experiment, osteogenic medium was prepared according to the instructions for the OriCell kit (purchased from Cyagen Biosciences Inc., catalog number: HUXMD-90021) used for osteogenic differentiation of human adipose-derived mesenchymal stromal cells, and then the following steps were performed. 2 x 10 cells 4 cell / cm 2 The cells were seeded into a 6-well plate at a density of 1000×, ... The culture medium supernatant was discarded. The cells were incubated in 2 mL of osteogenic medium, which was replaced once every 3 days, for 2 to 4 weeks, at which time significant calcium deposition was observed under an inverted microscope.
[0088] (3) Chondrogenic differentiation Before the experiment, chondrogenic medium was prepared according to the instructions for the OriCell kit (purchased from Cyagen Biosciences Inc., catalog number: HUXMD-90041) used for chondrogenic differentiation of human adipose-derived mesenchymal stromal cells, and then the following steps were performed. 0.1% gelatin was added to a 6-well plate, shaken gently to cover the bottom of the wells, allowed to stand for 30 minutes, the gelatin discarded, and the plate allowed to dry. 1 × 10 cells of passage 5 4 cell / cm 2 The cells were seeded at a density of 100 μg / well onto a 6-well plate coated with 0.1% gelatin, 2 mL of complete medium was added to each well, and the cells were cultured at 37°C and 5% CO2 conditions until the cells reached 80-90% confluence. The culture supernatant was discarded. Cells were induced in 2 mL of fresh chondrogenic medium (containing 20 μL of TGF-β3) and the chondrogenic medium was replaced once every 2-3 days for 2 weeks. Control wells were continuously cultured with complete medium. The cells were washed, fixed with 4% paraformaldehyde solution, and stained with Alcian blue for 30 min at room temperature. After washing three times with PBS (1×), images were taken with an inverted phase contrast microscope. As shown in Figure 1G and Figure 1H, which shows the differentiation status of multipotent mesenchymal stromal cells in an in vitro environment, multipotent mesenchymal stromal cells were induced to undergo adipogenic, osteogenic and chondrogenic differentiation, and as a result, it was shown that D1M1-P5 and D1M2-P5 were successfully induced into adipogenic cells, osteoblasts and chondroblasts, respectively. These results indicate that both passage 3 and passage 5 mesenchymal stromal cells cultured in different media are multipotent mesenchymal stromal cells and meet the recognized standards for mesenchymal stromal cell quality control.
[0089] Example 3 Animals treated with pluripotent mesenchymal stromal cells 1. Intravital Injection of Multipotent Mesenchymal Stromal Cells Male NCG mice aged 6 to 8 weeks (purchased from Gempharmatech Co., Ltd.) were randomly divided into groups. After fixing the mice, the injection site was disinfected. The fifth-passage hADSC samples (D1M1-P5 or D1M2-P5) that had passed quality control were resuspended in 0.9% saline and diluted to 1 × 10 6 The cells were slowly injected into each mouse via the tail vein at a dose of 100 cells / mouse. The control group was injected with 0.9% saline. After injection, the survival rate of the mice was recorded within 3 minutes. All 6 mice injected with D1M1-P5 died within 3 minutes, whereas all 6 mice injected with D1M2-P5 and 6 mice injected with 0.9% saline were observed to be alive within 3 minutes. After the observation was completed, the mice were anesthetized with Avertin and euthanized by cutting the abdominal aorta.
[0090] 2. Immunohistochemistry (1) Gathering materials The skin and muscles of the mouse were cut, the thoracic cavity was exposed, the right ventricle was punctured with a syringe, and 5 mL of 0.9% saline was slowly perfused throughout the body until the outflowing liquid was relatively clear with no obvious blood color. The lungs of the mouse were promptly harvested. Visual pathological observation was performed, and the tissues were fixed in 10% formalin solution for 2 days.
[0091] (2) Hematoxylin-eosin staining According to common laboratory procedures, the obtained lung tissues were dehydrated in gradient ethanol, embedded in paraffin, sectioned, stained with hematoxylin-eosin (HE), and finally observed under a light microscope. Figure 2A shows the pathological results of lung tissue after injection of D1M1-P5, D1M2-P5 or saline into mice, and compared with the control group, mice injected with D1M1-P5 showed pulmonary congestion and severe pulmonary embolism, whereas D1M2-P5 did not show any adverse reactions. Figure 2B also shows that mice injected with D1M1-P5 had a large number of venous thrombi in the lungs, and the density of the embolism was significantly higher than that of the D1M2-P5 group and the control group. Furthermore, fluorescent PKH26-labeled D1M1-P5 or D1M2-P5 was injected into a mouse model, and the number of PKH26-positive cells in the lungs was counted. As a result, as shown in Figures 2C and 2D, consistent with the immunohistochemical results, a large amount of PKH26 was detected in the lungs of mice that had developed thrombi. + D1M1-P5 were observed, indicating that mesenchymal stromal cells grown under different culture conditions underwent different biological processes or formed different lineages.
[0092] Example 4 Single-cell RNA sequencing To identify the heterogeneity of mesenchymal stromal cells in different media, we examined the gene expression profile of mesenchymal stromal cells at the single-cell level by performing single-cell RNA sequencing. The steps were as follows:
[0093] 1. Preparation of Single-cell Suspension The fifth passage hADSC samples (D1M1-P5 and D1M2-P5) were diluted with sample buffer to a cell suspension with a concentration of <1000 cells / μL. 1 μL of Calcein AM dye and 1 μL of Draq7 dye were added to 200 μL of the cell suspension to perform cell staining. The stained cell suspension was filtered through a 40 μm filter and placed in a BD Rhapsody® scanner to measure cell density and cell viability. Dilutions of the cell suspension were prepared based on the stock cell and buffer volumes obtained from the sample calculator function of the scanner.
[0094] 2. Single Cell Sorting The diluted cell suspension was loaded onto a Cartridge workflow equipped with 200,000 microwells (Cartridge Kit, purchased from BD Biosciences, catalog number: 633733), and the cell loading amount and doublet rate were analyzed to evaluate the single cell separation effect. After washing to remove unloaded cells, BD Rhapsody beads were loaded into Cartridge workflow and analyzed for bead and cell loading and doublet percentage to assess the number of beads bound in single cell wells. After washing to remove excess beads, the cell lysis solution was added to Cartridge workflow to lyse the cells. The mRNA contained in each cell was captured by the probe via the polyA / polyT on the surface of the BD Rhapsody beads, which have the same cell label (CL) and various molecular barcodes (UMI). The BD Rhapsody beads were collected from the Cartridge workflow into a centrifuge tube.
[0095] 3. Single-cell cDNA Synthesis and Library Construction First-strand cDNA from single cells was reverse-synthesized and libraries were constructed using the Cartridge kit (purchased from BD Bioscience, Catalog No. 633731) and the Whole Transcriptome Analysis (WTA) Amplification Kit (purchased from BD Bioscience, Catalog No. 633801). The following operations were performed according to the kit's instruction manual, which are briefly described below. The collected beads were washed, and the reverse transcription reagent (Table 4) was added and mixed with the beads, followed by incubation at 37° C. for 45 minutes.
[0096] [Table 4]
[0097] Exonuclease was added, incubated at 37°C for 30 minutes, and then incubated at 80°C for 20 minutes to remove probes that were not connected to mRNA on the bead surface. Random primer mix (Table 5) was added and incubated at 95°C for 5 min, 37°C at 1200 rpm for 5 min, 25°C at 1200 rpm for 15 min; primer extension mix (Table 6) was added and incubated at 25°C at 1200 rpm for 10 min, 37°C at 1200 rpm for 15 min, 45°C at 1200 rpm for 10 min, 55°C at 1200 rpm for 10 min, and the extended first strand cDNA was eluted with bead-free eluent.
[0098] [Table 5] [Table 6]
[0099] The random primer extension (RPE) products were added to a PCR amplification mixture (Table 7) containing universal and specific primers, and amplification was carried out using the process in Table 8, followed by enrichment and purification of the amplified products.
[0100] [Table 7] [Table 8]
[0101] The amplified products were used as templates for PCR using the Whole Transcriptome Index PCR Amplification Mix (Table 9), and amplification was performed according to the process in Table 10 (if the molar concentration of the amplified product is 1-2 nM, amplification was performed for 9 cycles; if the molar concentration of the amplified product is >2 nM, amplification was performed for 8 cycles). The new amplified products were enriched and purified to obtain single-cell sequencing libraries.
[0102] [Table 9] [Table 10]
[0103] 4. Single-cell Sequencing Library Quality The concentration of the single-cell sequencing library was measured by a Qubit instrument, and the fragment length of the single-cell sequencing library was measured by an Agilent 2100 bioanalyzer, which showed that the library concentration was 0.1-100 ng / μL and the fragment length of the library was 460-550 bp.
[0104] 5. Single-cell Sequencing The molar concentration of the single-cell sequencing library calculated based on the library concentration and fragment length was 1 to 100 nM. After dilution to a standard molar concentration of 0.2 to 2 nM, the sequencing control library PhiX, which has the same molar concentration as the single-cell sequencing library, was mixed in a ratio of single-cell sequencing library:sequencing control library = 1:(0.05 to 0.5) and sequencing was performed.
[0105] 6. Sequencing Data Quality Sequencing data were analyzed by BD cwl-runner 3.1 to assess the quality of the raw sequencing data. 5095 D1M1-P5 and 3249 D1M2-P5 clones were sequenced, with an average sequencing depth of 50K / cell.
[0106] Example 5. Clustering of subpopulations Raw sequencing data were converted to FASTQ format and the quality of the sequencing data was analyzed. The BD Rhapsody analysis pipeline v1.9.1 (BD Biosciences) was used for cell barcode identification, read alignment, and UMI quantification using default parameters.
[0107] 1. Data Preprocessing Quality control: sequences with read1 length < 60, read2 length < 42, read1 and read2 base quality < 20, and sequences with read1 single nucleotide frequency (SNF) ≥ 0.55 or read2 SNF ≥ 0.80 were filtered out. Alignment and annotation: Quality-controlled valid reads were aligned to the human reference genome GRCh38, and the alignment results were annotated. Gene Expression Matrix: The expressed read counts for each gene in all samples were merged (collapsed) and adjusted to molecular barcode (UMI) counts by recursive permutation error correction (RSEC). Putative cells were discriminated from background noise by second derivative analysis of all RSEC-adjusted UMI counts. The resulting output was a gene expression matrix with gene identities as columns and cell indices as rows.
[0108] 2. Cell Filtering The RSEC-adjusted UMI count matrix was imported into R 4.1.0. Gene expression data were analyzed using Seurat software 4.0.3. After singlets were identified, abnormal cells were excluded from downstream analysis by the median absolute deviation (MAD) method. Cells with a median mitochondria reads percentage greater than 3MAD, median expressed genes less than 3MAD, or median UMI count less than 3MAD were considered abnormal. To avoid the influence of confounding factors such as cell cycle stage, sequencing depth and percent mitochondrial, these confounding factors were removed from the analysis by Seurat.
[0109] 3. Dimensionality Reduction To obtain a two-dimensional projection of the population dynamics, we processed the top 2000 highly variable genes in the normalized gene barcode matrix by Seurat's principal component analysis (PCA), and performed dimensionality reduction on the matrix to obtain low-dimensional spatial information. We then performed uniform manifold approximation and projection (UMAP) to process the top 30 principal components (PCs), achieving cell visualization in two-dimensional space. The steps included the following: Normalize the data using the NormalizeData function (normalization.method = "LogNormalize") Select the top 2000 genes, ranked based on variance, as highly variable genes (HVG) using the FindVariableFeature function (selection.method="vst", nfeatures=2000); 2000 highly variable genes were normalized using the ScaleData function to remove noise due to factors such as the cell cycle. Reduce the dimensionality of the data using the RunPCA function (features = VariableFeatures (object = adsc)). Constructing a neighborhood graph using the shared nearest neighbor similarity algorithm (SNN) of the FindNeighbors function; Use the FindClusters function to adjust the parameters of the SNN model results (resolution = 0.1 ~ 1) to determine the number of cell subpopulations; Perform visualization and dimensionality reduction analysis using the RunUMAP function. Figure 3A shows the clustering results of cell subpopulations of D1M1-P5 and D1M2-P5, which included six different clusters (0-5), and there was a clear difference in the occupancy of each cluster in D1M1-P5 and D1M2-P5. Based on GO and KEGG, risk genes of mesenchymal stromal cells were excavated, and as shown in Figure 3B and Figure 3C, there was also a difference in the expression of each subpopulation for risk genes. This indicates that mesenchymal stromal cells generate heterogeneity in different media, and the gene expression profiles of D1M1-P5 and D1M2-P5 were completely different.
[0110] 4. Functional Clustering Analysis of Cell Subpopulations To convert the sparse gene expression matrix into a pathway score matrix, all genes in the gene expression matrix were scored based on classical pathways. Then, the pathway score matrix was subjected to dimensionality reduction and visualization to obtain the functional clustering results of cell subpopulations. A schematic diagram of the mechanism is shown in Figure 4. The steps are briefly described as follows: Pathway enrichment analysis was performed on single-cell gene expression data, and the canonical pathway scores in each cell were calculated using the ssGSEA, AUCell, and Seurat scoring functions to obtain a pathway score matrix. Dimensionality reduction and visualization were then performed based on the pathway score matrix as described above. As shown in Figure 5A, Figure 5B and Figure 5C, the clustering results by the three different scoring functions were the same. The cell subpopulations of D1M1-P5 (i.e., A2105C2P5) and D1M2-P5 (i.e., A2105C3P5) were distinguished and separated from each other. D1M1-P5 were both quality risk mesenchymal stromal cells, and D1M2-P5 were both non-quality risk mesenchymal stromal cells, indicating that mesenchymal stromal cells underwent significant functional changes after being cultured in different media, which is consistent with the results of the animal experiments in Example 2. The functional clustering process developed here can provide a valuable tool for identifying specific functional subpopulations based on their transcriptome profiles. By the cell culture method as shown in FIG. 6, the multipotent mesenchymal stromal cells derived from donor 1 were subcultured from the first to the third passage using M1 or M2 medium, and then the medium was replaced and the cells were subcultured up to the fifth passage. The quality of the mesenchymal stromal cells at the third and fifth passages was determined by functional clustering analysis. As a result, as shown in Figures 7A, 7B, and 7C, mesenchymal stromal cells cultured in M1 medium and mesenchymal stromal cells cultured in M2 medium were different cell subpopulations. All mesenchymal stromal cells cultured in M1 medium were quality risk mesenchymal stromal cells, and all mesenchymal stromal cells cultured in M2 medium were non-quality risk mesenchymal stromal cells. Heterogeneity occurs when mesenchymal stromal cells grow under different culture conditions. According to the animal experiment results in Figures 8A and 8B, D1M1-P3 and D1M2 / M1-P5 induced pulmonary embolism in mice, but D1M2-P3 and D1M1 / M2-P5 did not induce pulmonary embolism in mice, indicating the accuracy of the functional clustering results.
[0111] 5. Single-cell Functional Clustering of Mesenchymal Stromal Cells Based on the general steps of data preprocessing, cell filtering, dimensionality reduction and clustering analysis, the scRNA sequencing data of D1M1-P5, D1M2-P5, D2M1-P5, D2M2-P5, D3M1-P5 and D3M2-P5 were analyzed. D1M1-P5 and D1M2-P5 represent pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells from donor 1 and cultured in M1 or M2 medium for up to the fifth passage. D2M1-P5 and D2M2-P5 represent pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells from donor 2 and cultured in M1 or M2 medium for up to the fifth passage. D3M1-P5 and D3M2-P5 represent pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells from donor 3 and cultured in M1 or M2 medium for up to the fifth passage. Expression of differentially expressed genes was analyzed by Wilcoxon rank sum test with Seurat. Genes were identified as significantly differentially expressed genes with a false discovery rate (FDR) <0.05 and a minimum log fold change in expression between populations of 0.25. The differentially expressed genes in different clusters were analyzed by heat map analysis. As shown in Figure 9A and Figure 9B, the differentially expressed genes related to the pro-embolism pathways (intrinsic pathway formed by fibrin clot, extrinsic pathway formed by fibrin clot, and common pathway formed by fibrin clot) were upregulated in cluster 0 and cluster 3. Based on the genes defined by the heat map analysis, the cells in subpopulations 0 and 3 were analyzed again. As a result, as shown in Figures 9C and 9D, mesenchymal stromal cells cultured in M1 medium were mainly classified into the quality risk subpopulation (subpopulation 0), whereas mesenchymal stromal cells cultured in M2 medium were mainly classified into the non-quality risk subpopulation (subpopulation 0).
[0112] Example 6 Identification of Subpopulations In this example, a mesenchymal stromal cell quality prediction model was constructed based on decision tree, random forest, or support vector machine (SVM). The dataset is listed in Table 11. A schematic diagram of the mechanism is shown in Figure 10. D1M1-P5 and D1M2-P5 respectively indicate multipotent mesenchymal stromal cells obtained by subculturing primary multipotent mesenchymal stromal cells from donor 1 and cultured in M1 or M2 medium up to the fifth passage. D1M1-P3 and D1M2-P3 respectively indicate multipotent mesenchymal stromal cells obtained by subculturing primary multipotent mesenchymal stromal cells from donor 1 and cultured in M1 or M2 medium up to the third passage. D2M1-P5 and D2M2-P5 represent pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells derived from donor 2 and cultured in M1 or M2 medium up to passage 5, respectively. D2M3 / M2-P5 represent pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells derived from donor 2 and cultured in M3 medium (αMEM+5% Helios UltraGRO-Advanced) up to passage 3 and then in M2 medium up to passage 5.
[0113] [Table 11]
[0114] The steps were as follows: 1. Initial hyperparameters In the random forest models, the estimator (n_estimator) was 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000, and the maximum tree depth (max_depth) was 3, 5, or 7. In the support vector machine models, the regularization parameter C was 0.2, 0.6, 0.8, 1.0, 1.2, 1.6, 2.0, 2.2, 2.6, and 3.0, and the kernel parameter (kemel) was linear, "poly", "rbf", or "sigmoid".
[0115] 2. Feature Selection A machine learning method combining recursive feature reduction and cross-validation was used to rank each gene in the training set for its importance in distinguishing quality risk from non-quality risk mesenchymal stromal cells. The most significant genes were added one by one, and the accuracy rate of 10-fold cross-validation was calculated to determine the matching feature genes and the number of feature genes. As shown in FIG. 11, when the most important gene was selected as the feature gene, the accuracy rates of the models with different normalization parameters C in the 10-fold cross-validation in the training set were all above 94%, and when the most important 13 genes (TAGLN, EFEMP1, TPM1, CLU, PTX3, IER3, IGFBP7, MFAP5, IL6, LUM, SERPINE2, CRIM1 and RHOB) were selected as the feature genes, the accuracy rates of the models with different normalization parameters C in the 10-fold cross-validation in the training set all reached 100%.
[0116] 3. Model derivation A linear SVM model was developed using 13 feature genes, and the model coefficient matrix (model weight matrix) was optimized by cross-validation to indicate the importance score of the feature genes. The models were trained with test set 1, test set 2, test set 3 and test set 4, respectively, and the regularization parameter C was adjusted according to the prediction accuracy. Based on the test results shown in Table 12, the linear SVM model with the best representation in all test sets (C=0.0005) was selected as the mesenchymal stromal cell quality prediction model.
[0117] [Table 12]
[0118] As shown in Table 13, the predicted results of the determined mesenchymal stromal cell quality prediction model (support vector machine model, model complexity parameter C = 0.0005) for different types of mesenchymal stromal cells have good measurement accuracy, precision, recall and F1 score in four test sets. The determined 13 feature genes and their corresponding weight coefficients are shown in Table 14.
[0119] [Table 13] [Table 14]
[0120] 4. Mesenchymal Stromal Cell Quality Score at Single-cell Level Based on the expression levels of the identified 13 characteristic genes and the weighting coefficients of each characteristic gene determined by the mesenchymal stromal cell quality prediction model, the quality score of mesenchymal stromal cells at the single cell level was calculated using the following function to quantify the quality risk of a single mesenchymal stromal cell.
[0121]
number
[0122] Wherein, Gi is the expression level of the i-th feature gene in a single mesenchymal stromal cell, Wi is the weight coefficient of the i-th feature gene, and n is the quantity of the feature gene. A positive value of Wi indicates that an increase in the expression of the feature gene promotes the quality risk of mesenchymal stromal cells, and a negative value of Wi indicates that an increase in the expression of the feature gene suppresses the quality risk of mesenchymal stromal cells.
[0123] The quality scores of mesenchymal stromal cells and the risk score thresholds in the four test sets were evaluated using receiver operating characteristic (ROC) curves and areas under the curve (AUC).
[0124] FIG. 12 shows the ROC curves and corresponding AUCs of test set 1, test set 2, test set 3 and test set 4. The highest value of the ROC curve (the one with the highest sensitivity and specificity) was taken as the threshold value for determining whether the mesenchymal stromal cells of the test set were quality risk mesenchymal stromal cells or non-quality risk mesenchymal stromal cells. According to the ROC curve, the quality score thresholds of the four test sets were defined as 3.961 (AUC=1), 3.961 (AUC=1), 5.312 (AUC=0.986) and 6.680 (AUC=0.993). Specific results are shown in FIG. 13A, FIG. 13B, FIG. 13C and FIG. 13D.
[0125] Example 7 Validation of mesenchymal stromal cell quality prediction model According to the 13 identified feature genes and the weight coefficients of feature genes (Table 14) determined from the mesenchymal stromal cell quality prediction model, the expression levels of the feature genes at the single cell level of D1M1 / M2-P5 and D1M2 / M1-P5 were examined. Based on the function, the quality scores of D1M1 / M2-P5 and D1M2 / M1-P5 were calculated. The quality risk threshold was 3.961.
[0126] As a result, as shown in Figure 14, 99.90% of D1M2 / M1-P5 were mesenchymal stromal cells with a quality risk and 0.10% were non-quality risk mesenchymal stromal cells, whereas 0.24% of D1M1 / M2-P5 were mesenchymal stromal cells with a quality risk and 99.76% were non-quality risk mesenchymal stromal cells. The prediction results are consistent with the functional clustering results of the cell subpopulations in Figures 7A, 7B, and 7C, and the results of the animal experiments shown in Figures 8A and 8B. This indicates that the quality prediction model can accurately predict the quality risk of mesenchymal stromal cells.
[0127] In the present invention, the specific methods of the present invention are described in the above examples, but the present invention is not limited to these specific methods, that is, it does not mean that the present invention must be implemented by relying on the above specific methods. Any improvements to the present invention, equivalent replacement of each raw material of the product of the present invention, addition of auxiliary ingredients, selection of specific methods, etc. are all within the protection scope and disclosure scope of the present invention.
Claims
1. Obtaining expression levels of characteristic genes associated with stem cell quality; Calculating a stem cell quality score based on the expression levels of the feature genes and the weighting coefficients of the feature genes; Evaluating stem cell quality based on stem cell quality score A method for evaluating stem cell quality, comprising:
2. The method for evaluating stem cell quality according to claim 1 , wherein the characteristic genes associated with stem cell quality are determined at the single cell level.
3. The method for determining characteristic genes related to stem cell quality comprises: obtaining single cell gene expression data of stem cells and specific quality attributes, forming a dataset divided into a training set and a test set; Training a supervised machine learning model using the training set, adjusting parameters of the supervised machine learning model using cross-validation and a test set, and determining a stem cell quality prediction model; The method for evaluating stem cell quality according to claim 1 or 2, comprising determining characteristic genes associated with stem cell quality using a stem cell quality prediction model.
4. The method for determining the weight coefficients of the feature genes comprises: The method for evaluating stem cell quality according to any one of claims 1 to 3, further comprising determining weighting coefficients of characteristic genes using a stem cell quality prediction model.
5. The method for obtaining single cell gene expression data of stem cells comprises: The method for evaluating stem cell quality according to any one of claims 1 to 4, comprising obtaining single-cell gene expression data of stem cells by performing single-cell RNA sequencing on the stem cells.
6. The method for determining the specific quality attribute comprises: determining specific quality attributes based on the stem cell culture microenvironment; Determining specific quality attributes based on apparent genetic data of single cell genes of stem cells; or determining certain quality attributes based on single cell gene expression data of the stem cells; determining certain quality attributes based on single cell gene expression data of the stem cells; Perform pathway enrichment analysis on single-cell gene expression data of stem cells and calculate pathway scores for each stem cell to obtain a pathway score matrix; A method for evaluating stem cell quality according to any one of claims 1 to 5, comprising performing bioinformatics analysis on a pathway score matrix to obtain stem cell clustering results as specific quality attributes of stem cells.
7. performing a bioinformatics analysis on the pathway score matrix; The method for evaluating stem cell quality according to any one of claims 1 to 6, comprising performing dimensionality reduction and clustering processing on a pathway score matrix.
8. A method for evaluating stem cell quality according to any one of claims 1 to 7, characterized in that the function of the stem cell quality score is as follows: [0010] (In the formula, Gi is the expression level of the i-th feature gene, Wi is the weight coefficient of the i-th feature gene, and n is the quantity of the feature gene.)
9. The method for evaluating stem cell quality based on the stem cell quality score comprises: If the stem cell quality score is greater than or equal to the stem cell quality risk threshold, the stem cell is a quality risk stem cell; The method for evaluating stem cell quality according to any one of claims 1 to 8, wherein when the stem cell quality score is less than the stem cell quality risk threshold, the stem cell is a non-risk-quality stem cell.
10. The method for determining a stem cell quality risk threshold comprises: analyzing the stem cell quality score of the data set according to a receiver operating characteristic curve, the highest point of which is a threshold for stem cell quality risk, and an area under the curve; A method for evaluating stem cell quality according to any one of claims 1 to 9, wherein the dataset comprises single-cell gene expression data of stem cells labeled with known specific quality attributes.
11. The method for evaluating stem cell quality according to any one of claims 1 to 10, wherein the supervised machine learning model comprises any one of a perceptron model, a K-nearest neighbor model, a naive Bayes model, a decision tree model, a logistic regression, a support vector machine, a random forest, a boosting model, an EM algorithm, or a conditional random field.
12. The method for evaluating stem cell quality according to any one of claims 1 to 11, wherein the characteristic genes related to stem cell quality include at least three genes selected from the group of genes consisting of TAGLN, EFEMP1, TPM1, CLU, PTX3, IER3, IGFBP7, MFAP5, IL6, LUM, SERPINE2, CRIM1 and RHOB.
13. The method for evaluating stem cell quality according to any one of claims 1 to 12, wherein the stem cells include any one or a combination of at least two of adult stem cells, embryonic stem cells, induced pluripotent stem cells, or stem cells transformed from mature somatic cells, and their derived cells.
14. The method for evaluating stem cell quality according to any one of claims 1 to 13, wherein the stem cells comprise any one or a combination of at least two of mesenchymal stem cells, mesenchymal stromal cells, multipotent stromal cells, multipotent mesenchymal stromal cells, or medicinal signaling cells.
15. The method for evaluating stem cell quality according to any one of claims 1 to 14, wherein the stem cells comprise any one or a combination of at least two of the following: adipose-derived stem cells, umbilical cord mesenchymal stem cells, placenta-derived stem cells, bone marrow mesenchymal stem cells, dental marrow mesenchymal stem cells, menstrual blood-derived stem cells, amniotic epithelial stem cells, and bronchial basal cells.
16. Perform pathway enrichment analysis on single-cell gene expression data of stem cells and calculate pathway scores for each cell to obtain a pathway score matrix. A method for single cell functional clustering of stem cells, comprising: performing bioinformatics analysis on the pathway score matrix to obtain single cell subpopulations of stem cells.
17. performing a bioinformatics analysis on the pathway score matrix; The method for single-cell functional clustering of stem cells described in claim 16, which comprises performing dimensionality reduction and clustering processing on the pathway score matrix.
18. The method for single cell functional clustering of stem cells according to claim 16 or 17, comprising analyzing differentially expressed genes of single cell subpopulations of stem cells, selecting a single cell subpopulation in which one or more differentially expressed genes associated with a pathway are present, and performing dimensionality reduction and clustering processing using the differentially expressed genes to obtain single cell functional clustering of stem cells.
19. A combination of characteristic genes including at least three genes selected from the group consisting of TAGLN, EFEMP1, TPM1, CLU, PTX3, IER3, IGFBP7, MFAP5, IL6, LUM, SERPINE2, CRIM1 and RHOB.
20. Use of at least three genes selected from the group consisting of TAGLN, EFEMP1, TPM1, CLU, PTX3, IER3, IGFBP7, MFAP5, IL6, LUM, SERPINE2, CRIM1 and RHOB for evaluating stem cell quality.
21. a processor and a memory storing instructions executable by the processor; A server in which the processor executes the stem cell quality assessment method described in any one of claims 1 to 15 or the stem cell single cell functional clustering method described in any one of claims 16 to 18.
22. A computer-readable medium storing a computer program for executing the stem cell quality assessment method described in any one of claims 1 to 15 or the single-cell functional clustering method of stem cells described in any one of claims 16 to 18.
Citation Information
Patent Citations
Method for evaluating quality of pluripotent stem cells
CN113658636A
Molecular diagnostic tests for cancer
JP2013537045A
Enhanced placental stem cells and uses thereof
JP2016512433A
Method for evaluating quality of stem cell and kit for evaluating quality of stem cell
JP2018117582A
saRNA composition and method of use
JP2018512876A
Cited By
Mesenchymal stromal cell quality assessment system
JP2024541583A
Mesenchymal stromal cell quality evaluation system
JP7794975B2
